Investigation of a therapy for prostate cancer by inhibition of GGCT expression

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K20084
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Urology
• Research Institution: Shiga University of Medical Science
• Principal Investigator: Hanada Eiki 滋賀医科大学, 医学部, 助教 (40555067)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: γグルタミルシクロトランスフェラーゼ / RNA干渉 / 前立腺癌

Outline of Final Research Achievements

We studied a therapy for prostate cancer by inhibition of GGCT expression. In the immunohisotochemical study using tissue microarray, GGCT was highly expressed in two sections out of 9 sections (22%) of normal human prostate tissue. On the other hand, GGCT was highly expressed in 35 sections out of 40 sections (78%) of prostate cancer tissue. A significant antiproliferative effect via GGCT-targeting siRNA was shown in prostate cancer cell lines, and combination treatment consisting of Docetaxel and GGCT-targeting siRNA reduced cell viability more than the treatment with Docetaxel alone. Therefore, a therapy for prostate cancer by inhibition of GGCT expression may be an effective method.

Free Research Field

泌尿器癌